Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.

More about this publication

Annals of oncology : official journal of the European Society for Medical Oncology
  • Volume 32
  • Issue nr. 9
  • Pages 1194-1197
  • Publication date 01-09-2021

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.